Gemmus Pharma Inc.News and Events
Nov 17, 2011
Professor Richard Horuk has been elected to the Gemmus Pharma board of directors. Dr. Horuk joins existing members Dr. Faulds and Dr. Guilford. "Richard's chemokine project management experience will be a real asset to the board," said Daryl Faulds, CEO.
Jan 2, 2011
The San Francisco Office of Economic and Workforce Development certifies State Enterprise Zone tax credits for Gemmus Pharma.
October 29, 2010
The US Department of the Treasury awards Gemmus Pharma a Qualifying Therapeutic Discovery Grant. Gemmus Pharma was selected to receive a grant of over $162,000 to further its work for the treatment of influenza.
June 28, 2010
National Institutes of Health (NIH) awards Gemmus Pharma a Small Business Innovation Research Grant (SBIR). Gemmus Pharma was selected to receive a grant of over $231,000 to further its work for the treatment of influenza.
Jan 12, 2010
A commercial collaboration partner agrees to fund a study to compare the efficacy of GP1001, a proprietary antiviral therapeutic and the two drugs in combination for the treatment of influenza A H3N2 infection in BALB/c mice. The study begins at Utah State University.
Jan 5, 2010
Based on positive results for influenza A H1N1 the NIH-NIAID agrees to fund a Gemmus-sponsored study to compare the efficacy of GP1001, oseltamivir and the two drugs in combination for delayed treatment of influenza A H1N1 infection in BALB/c mice. The study begins at Utah State University.
July 2, 2009
NIH-NIAID agrees to fund a Gemmus-sponsored study to compare the efficacy of GP1001, oseltamivir and the two drugs in combination for influenza A H1N1 infection in BALB/c mice.
July 1, 2009
Gemmus Pharma moves laboratory operations and office space to 409 Illinois Street Suite 4004, San Francisco CA 94158. Our contact information has changed.
July 1, 2009
Gemmus Pharma joins QB3 Mission Bay.
The goal of QB3 Mission Bay is to help entrepreneurs move efficiently from conducting biomedical research to creating successful biotech companies. Through QB3 Gemmus Pharma obtains access to world-class facilities and helps the sustained growth of the California economy.
By virtue of our status within QB3 Mission Bay adjacent to the new University of California, San Francisco campus, Gemmus Pharma will be able to make use of the UCSF library with access to over 2,500 journals, dozens of seminars each week, the intellectual vitality, and the opportunity for collaboration with the UCSF academic community.
June 19, 2009
Gemmus Pharma enters into a specialized service agreement with Utah State University, a state-owned educational institution, dedicated to serving the public through learning, discovery, and engagement.
Utah State University and Gemmus Pharma believe this specialized service agreement with the Institute of Antiviral Reseach is of mutual interest and benefit to the University and Gemmus, will further the University's instructional and research objectives in a manner consistent with its status as a non-profit, tax-exempt, educational institution, and may produce benefits for both the University and Gemmus Pharma through inventions, improvements, and/or discoveries.
March 20, 2009
Gemmus Pharma presents to the prestigious panel of business, labor, community and government leaders assembled by Congresswoman Jackie Speier as her Citizens Oversight Panel.
Documents related to the Gemmus presentation can be viewed on Congresswoman Speier's official website: www.speier.house.gov
October 2, 2008
The Board of Directors of Gemmus Pharma Inc. approves in its entirety an equity incentive program for employees, non-employee Board members and consultants in the service of the Corporation.
October 2, 2008
Gemmus Pharma moves laboratory operations to the B-Bridge Bioincubator facility in Mountain View.